INSYS Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019
INSYS Therapeutics, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported net revenue was $7,630,000 against $23,911,000 a year ago. Loss from operations was $122,113,000 against $20,233,000 a year ago. Net loss was $123,844,000 against $20,370,000 a year ago. Basic loss per common share was $1.66 against $0.28 a year ago.